[A review of immune-related adverse events associated with immunotherapy].
Zhonghua Zhong Liu Za Zhi
; 42(1): 17-21, 2020 Jan 23.
Article
en Zh
| MEDLINE
| ID: mdl-32023764
ABSTRACT
Immune checkpoint inhibitors have been approved for clinical application in China. However, the increased immune-related adverse event (irAE) needs more attention. This review summarized the incidence, characteristic clinical manifestation and treatment of irAEs associated with programmed cell death protein-1(PD-1) and programmed cell death ligand-1(PD-L1) inhibitors. To have a deep insight into irAE, the potential mechanisms, the different incidences of cancer types, influencing factors and the direction of future research were also discussed here to provide guidance for clinical oncologist to identify and monitor irAE.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Inmunoterapia
/
Neoplasias
Tipo de estudio:
Guideline
/
Incidence_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Humans
País/Región como asunto:
Asia
Idioma:
Zh
Revista:
Zhonghua Zhong Liu Za Zhi
Año:
2020
Tipo del documento:
Article
País de afiliación:
China